{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:04:33Z","timestamp":1790777073787,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pediatric Hospital Epidemiology and Outcomes Research Training Fellowship","award":["5 T32 HD 60550-9"],"award-info":[{"award-number":["5 T32 HD 60550-9"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucocorticoid exposure is a significant driver of morbidity in children with systemic juvenile idiopathic arthritis (sJIA). We determined the effect of early initiation of biologic therapy (IL-1 or IL-6 inhibition) on glucocorticoid exposure in hospitalized patients with new-onset sJIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We emulated a pragmatic sequence of trials (\u201cpseudo-trials\u201d) of biologic initiation in children (\u2264 18\u2009years) hospitalized with new-onset sJIA utilizing retrospective data from an administrative database from 52 tertiary care children\u2019s hospitals from 2008 to 2019. Eligibility window, treatment assignment and start of follow-up between biologic and non-biologic study arms were aligned for each pseudo-trial. Patients in the source population could meet eligibility criteria at several timepoints. Mixed-effects logistic regression was used to determine the effect of biologic initiation on in-hospital glucocorticoid exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four hundred sixty-eight children met eligibility criteria, of which 19% received biologic therapy without preceding or concomitant initiation of immunomodulatory medications. This proportion significantly increased over time during the study period (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.01). 1451 trial subjects were included across 4 pseudo-trials with 71 assigned to the biologic arm and 1380 assigned to the non-biologic arm. After adjustment, there was a trend toward decreased odds of glucocorticoid initiation in the biologic arm compared to the non-biologic arm (OR 0.39, 95% CI [0.13, 1.15]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic initiation in children hospitalized with new-onset sJIA significantly increased over time and may be associated with reduced glucocorticoid exposure. The increasing use of first-line biologic therapy may lead to clinically relevant reductions in treatment-related adverse effects of glucocorticoid-reliant therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00597-z","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:04:33Z","timestamp":1625465073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-2343","authenticated-orcid":false,"given":"Rosemary G.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-8171","authenticated-orcid":false,"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Katcoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8224-4281","authenticated-orcid":false,"given":"Brian T.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-0443","authenticated-orcid":false,"given":"Pamela F.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"issue":"12","key":"597_CR1","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1136\/ard.2003.014886","volume":"63","author":"G Horneff","year":"2004","unstructured":"Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638\u201344. https:\/\/doi.org\/10.1136\/ard.2003.014886.","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"597_CR2","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340\u20137. https:\/\/doi.org\/10.1001\/jama.2011.1671.","journal-title":"JAMA"},{"key":"597_CR3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kes019","volume":"51","author":"K Minden","year":"2012","unstructured":"Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51:1407\u201315.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"597_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1542\/pir.16-7-266","volume":"16","author":"JD Spahn","year":"1995","unstructured":"Spahn JD, Kamada AK. Special considerations in the use of glucocorticoids in children. Pediatr Rev. 1995;16(7):266\u201372. https:\/\/doi.org\/10.1542\/pir.16-7-266.","journal-title":"Pediatr Rev"},{"issue":"7","key":"597_CR5","first-page":"1189","volume":"20","author":"J Reeve","year":"1993","unstructured":"Reeve J, Loftus J, Hesp R, Ansell BM, Wright DJ, Woo PMM. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. J Rheumatol. 1993;20(7):1189\u201395.","journal-title":"J Rheumatol"},{"key":"597_CR6","doi-asserted-by":"crossref","unstructured":"Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep. 2014;6:21:6\u201321.","DOI":"10.12703\/P6-21"},{"issue":"25","key":"597_CR7","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1205099.","journal-title":"N Engl J Med"},{"issue":"25","key":"597_CR8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","journal-title":"N Engl J Med"},{"issue":"10","key":"597_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss P, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. Update of the 2011 American College of Rheumatology Recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Rheumatol. 2013;65(10):2499\u2013512. https:\/\/doi.org\/10.1002\/art.38092.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"597_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheumatol. 2011;63(2):545\u201355. https:\/\/doi.org\/10.1002\/art.30128.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"597_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"S Vastert","year":"2014","unstructured":"Vastert S, de Jager W, Noordman B, Holzinger D, Kuis W, Prakken B, et al. Effectiveness of first-line treatment with recombinant Interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034\u201343. https:\/\/doi.org\/10.1002\/art.38296.","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"597_CR12","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1007\/s10067-018-4297-6","volume":"37","author":"H Baris","year":"2018","unstructured":"Baris H, Anderson E, Sozeri B, Dedeoglu F. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis. Clin Rheumatol. 2018;37(12):3263\u201373. https:\/\/doi.org\/10.1007\/s10067-018-4297-6.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"597_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3899\/jrheum.180331","volume":"46","author":"B Saccomanno","year":"2019","unstructured":"Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, Guariento A, et al. Predictors of effectiveness of Anakinra in systemic juvenile idiopathic arthritis. J Rheumatol. 2019;46(4):416\u201321. https:\/\/doi.org\/10.3899\/jrheum.180331.","journal-title":"J Rheumatol"},{"issue":"7","key":"597_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"T Haar","year":"2019","unstructured":"Haar T, van Diikhuizen EH, Swart JF, van Roven-Kerkhof A, El Idrissi A, Leek AP, et al. Treat-to-target using first-line recombinant Interleukin-1 receptor antagonist Monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. 2019;71(7):1163\u201373. https:\/\/doi.org\/10.1002\/art.40865.","journal-title":"Arthritis Rheumatol"},{"key":"597_CR15","doi-asserted-by":"publisher","unstructured":"Peterson R, Xiao R, James K, Katcoff H, Fisher B, Weiss P. Variation in treatment of children hospitalized with new-onset systemic juvenile idiopathic arthritis in the United States. Arthritis Care Res. 2020. Accepted Author Manuscript. https:\/\/doi.org\/10.1002\/acr.24417.","DOI":"10.1002\/acr.24417"},{"issue":"6","key":"597_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10654-017-0287-2","volume":"32","author":"X Garc\u00eda-Alb\u00e9niz","year":"2017","unstructured":"Garc\u00eda-Alb\u00e9niz X, Hsu J, Hern\u00e1n MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. Eur J Epidemiol. 2017;32(6):495\u2013500. https:\/\/doi.org\/10.1007\/s10654-017-0287-2.","journal-title":"Eur J Epidemiol"},{"key":"597_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"M Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n M, Sauer B, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.04.014.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"597_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford M, Burgos-Vargas R, Cuttica R, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus. J Rheumatol. 2019;46(2):190\u20137. https:\/\/doi.org\/10.3899\/jrheum.180168.","journal-title":"J Rheumatol"},{"issue":"8","key":"597_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"597_CR20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766\u201379. https:\/\/doi.org\/10.1097\/EDE.0b013e3181875e61.","journal-title":"Epidemiology."},{"issue":"1","key":"597_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/M16-0758","volume":"166","author":"X Garc\u00eda-Alb\u00e9niz","year":"2017","unstructured":"Garc\u00eda-Alb\u00e9niz X, Hsu J, Bretthauer M, Hern\u00e1n M. Effectiveness of screening colonoscopy to prevent colorectal Cancer among Medicare beneficiaries aged 70\u201379 years: a prospective observational study. Ann Intern Med. 2017;166(1):18\u201326. https:\/\/doi.org\/10.7326\/M16-0758.","journal-title":"Ann Intern Med"},{"issue":"1","key":"597_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","volume":"22","author":"G Danaei","year":"2013","unstructured":"Danaei G, Rodr\u00edguez LAG, Cantero OF, Logan R, Hern\u00e1n MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22(1):70\u201396. https:\/\/doi.org\/10.1177\/0962280211403603.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"597_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","volume":"15","author":"Y Kimura","year":"2017","unstructured":"Kimura Y, Grevich S, Beukelman T, Morgan E, Nigrovic P, Mieszkalski K. Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans. Pediatr Rheumatol Online J. 2017;15(1):23. https:\/\/doi.org\/10.1186\/s12969-017-0157-1.","journal-title":"Pediatr Rheumatol Online J"},{"key":"597_CR24","unstructured":"Onel K. 2020 ACR guideline for the treatment of JIA: therapeutic approaches for Oligoarthritis, TMJ arthritis, and systemic JIA, medication monitoring, immunizations and non- pharmacologic therapies [conference presentation]. ACR Convergence. 2020;2020."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00597-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00597-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:12:39Z","timestamp":1625465559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00597-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00597-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-133377\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"16 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and determined to be exempt by the Children\u2019s Hospital of Philadelphia (CHOP) Internal Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}